CHAOJU EYE CARE (02219) announced on November 17, 2025, that its board of directors has resolved to repurchase up to HK$50 million worth of the company's shares in the open market from time to time, starting November 17, 2025. This decision is based on the share repurchase mandate approved by shareholders at the annual general meeting held on June 6, 2025, and any subsequent renewals or amendments as applicable.
The company believes the share repurchase demonstrates confidence in its business outlook and prospects, which will ultimately benefit the company and create value for shareholders. Depending on market conditions, the board may increase the maximum repurchase amount under the mandate. If such an adjustment is made, the company will promptly announce it in compliance with listing rules.
The board confirms that the company has sufficient financial resources to execute the repurchase while maintaining a strong financial position.
Comments